ASXL1: A Drug Target / Disease Biomarker (G171023)

Target Name: ASXL1

NCBI ID: G171023

ASXL1

ASXL1: A Drug Target / Disease Biomarker

The ASXL1 gene, also known as ALX1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer. The ASXL1 gene is located on chromosome 6 and encodes a protein known as ALX1, which is a key regulator of the T-cell receptor (TCR), a protein that is responsible for cell survival and growth.

The discovery of the ASXL1 gene as a potential drug target or biomarker comes from a team of researchers led by Dr. Persis Zamvakas, a renowned cancer researcher at the University of Melbourne. The team conducted a series of experiments to investigate the role of the ASXL1 gene in cancer development and treatment.

One of the key findings of the study was that overexpression of the ASXL1 gene was associated with cancer progression and a poor prognosis. The researchers found that high levels of ASXL1 expression were associated with poor outcomes in patients with various types of cancer, including breast, ovarian, and colorectal cancers.

The team also found that inhibiting the ASXL1 gene was a promising approach for cancer treatment. They administered a small molecule inhibitor to cells that overexpressed the ASXL1 gene, and found that the inhibitor significantly reduced the growth of cancer cells.

Another promising aspect of the ASXL1 study is its potential as a biomarker. The researchers found that ASXL1 expression was associated with poor prognosis in patients with breast cancer, and that high levels of ASXL1 were associated with the development of metastasis.

The team is now working on developing a diagnostic test for ASXL1 to aid in the early detection of cancer. They are also exploring the use of ASXL1 as a target for cancer immunotherapy, where antibodies are used to target and destroy cancer cells.

In conclusion, the ASXL1 gene has shown promising potential as a drug target or biomarker for various diseases, including cancer. The inhibition of ASXL1 expression is a promising approach for cancer treatment, and its potential as a biomarker for cancer detection is an exciting area of research. Further studies are needed to fully understand the role of ASXL1 in cancer development and treatment.

Protein Name: ASXL Transcriptional Regulator 1

Functions: Probable Polycomb group (PcG) protein involved in transcriptional regulation mediated by ligand-bound nuclear hormone receptors, such as retinoic acid receptors (RARs) and peroxisome proliferator-activated receptor gamma (PPARG) (PubMed:16606617). Acts as coactivator of RARA and RXRA through association with NCOA1 (PubMed:16606617). Acts as corepressor for PPARG and suppresses its adipocyte differentiation-inducing activity (By similarity). Non-catalytic component of the PR-DUB complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-119' (H2AK119ub1) (PubMed:20436459). Acts as a sensor of N(6)-methyladenosine methylation on DNA (m6A): recognizes and binds m6A DNA, leading to its ubiquitination and degradation by TRIP12, thereby inactivating the PR-DUB complex and regulating Polycomb silencing (PubMed:30982744)

The "ASXL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ASXL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets